These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 11464890)

  • 1. Somatostatin receptor type 2 gene expression in neuroblastoma, measured by competitive RT-PCR, is related to patient survival and to somatostatin receptor imaging by indium -111-pentetreotide.
    Orlando C; Raggi CC; Bagnoni L; Sestini R; Briganti V; La Cava G; Bernini G; Tonini GP; Pazzagli M; Serio M; Maggi M
    Med Pediatr Oncol; 2001 Jan; 36(1):224-6. PubMed ID: 11464890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors.
    Briganti V; Sestini R; Orlando C; Bernini G; La Cava G; Tamburini A; Raggi CC; Serio M; Maggi M
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2385-91. PubMed ID: 9815638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitation of somatostatin receptor type 2 gene expression in neuroblastoma cell lines and primary tumors using competitive reverse transcription-polymerase chain reaction.
    Sestini R; Orlando C; Peri A; Tricarico C; Pazzagli M; Serio M; Pagani A; Bussolati G; Granchi S; Maggi M
    Clin Cancer Res; 1996 Oct; 2(10):1757-65. PubMed ID: 9816127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative determination of sst2 gene expression in neuroblastoma tumor predicts patient outcome.
    Raggi CC; Maggi M; Renzi D; Calabrò A; Bagnoni ML; Scaruffi P; Tonini GP; Pazzagli M; De Bernardi B; Bernini G; Serio M; Orlando C
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3866-73. PubMed ID: 11061551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type-2 somatostatin receptor mRNA levels in breast and colon cancer determined by a quantitative RT-PCR assay based on dual label fluorogenic probe and the TaqMan technology.
    Pinzani P; Orlando C; Raggi CC; Distante V; Valanzano R; Tricarico C; Maggi M; Serio M; Pazzagli M
    Regul Pept; 2001 Jun; 99(2-3):79-86. PubMed ID: 11384768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of 17q gain and promoter polymorphisms on mRNA expression of somatostatin receptor type 2 in neuroblastoma.
    Simi L; Pinzani P; Raggi CC; Pazzagli M; Orlando C
    Clin Chim Acta; 2007 Sep; 384(1-2):149-54. PubMed ID: 17678886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
    Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
    Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma.
    Kaneko S; Ohira M; Nakamura Y; Isogai E; Nakagawara A; Kaneko M
    J Cancer Res Clin Oncol; 2007 Mar; 133(3):185-92. PubMed ID: 17028906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of somatostatin receptor expression in vivo is correlated to di- or tetraploid 1p36-deleted neuroblastomas.
    Schilling FH; Ambros PF; Bihl H; Martinsson T; Ambros IM; Borgström P; Jacobsson H; Falkmer UG; Treuner J; Kogner P
    Med Pediatr Oncol; 2001 Jan; 36(1):56-60. PubMed ID: 11464907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-111 pentetreotide scintigraphy in patients with neuroblastoma. Comparison with I-131 MIBG, N-Myc oncogene amplification, and patient outcome.
    Shalaby-Rana E; Majd M; Andrich MP; Movassaghi N
    Clin Nucl Med; 1997 May; 22(5):315-9. PubMed ID: 9152532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma.
    de Souza DR; Sanabani SS; de Souza AC; Filho Odone V; Epelman S; Bendit I
    Pediatr Blood Cancer; 2011 May; 56(5):749-56. PubMed ID: 21154590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYCN protein expression as a predictor of neuroblastoma prognosis.
    Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
    Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The high level of hCDC10 gene expression in neuroblastoma may be associated with favorable characteristics of the tumor.
    Nagata T; Takahashi Y; Asai S; Ishii Y; Mugishima H; Suzuki T; Chin M; Harada K; Koshinaga S; Ishikawa K
    J Surg Res; 2000 Aug; 92(2):267-75. PubMed ID: 10896833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients.
    Chang HH; Tseng YF; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Jou ST; Hsu WM; Jeng YM
    Mod Pathol; 2020 Apr; 33(4):531-540. PubMed ID: 31695155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-amplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma.
    Manohar CF; Salwen HR; Brodeur GM; Cohn SL
    Genes Chromosomes Cancer; 1995 Nov; 14(3):196-203. PubMed ID: 8589036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients.
    van Wezel EM; Decarolis B; Stutterheim J; Zappeij-Kannegieter L; Berthold F; Schumacher-Kuckelkorn R; Simon T; Fiocco M; van Noesel MM; Caron HN; van der Schoot CE; Hero B; Tytgat GAM
    Eur J Cancer; 2016 Feb; 54():149-158. PubMed ID: 26796600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of MIBG and pentetreotide scintigraphy in children with neuroblastoma. Is the expression of somatostatin receptors a prognostic factor?
    Kropp J; Hofmann M; Bihl H
    Anticancer Res; 1997; 17(3B):1583-8. PubMed ID: 9179198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative evaluation of somatostatin receptor subtype 2 expression in sporadic colorectal tumor and in the corresponding normal mucosa.
    Casini Raggi C; Calabrò A; Renzi D; Briganti V; Cianchi F; Messerini L; Valanzano R; Cameron Smith M; Cortesini C; Tonelli F; Serio M; Maggi M; Orlando C
    Clin Cancer Res; 2002 Feb; 8(2):419-27. PubMed ID: 11839658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.
    Oberthuer A; Kaderali L; Kahlert Y; Hero B; Westermann F; Berthold F; Brors B; Eils R; Fischer M
    Clin Cancer Res; 2008 Oct; 14(20):6590-601. PubMed ID: 18927300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuron-specific hel-N1 and HuD as novel molecular markers of neuroblastoma: a correlation of HuD messenger RNA levels with favorable prognostic features.
    Ball NS; King PH
    Clin Cancer Res; 1997 Oct; 3(10):1859-65. PubMed ID: 9815574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.